This Month in Psychopharmacology

Stimulant Medication Use and Risk of Psychotic Experiences

Recent post marketing surveillance and observational studies have s...

Read More

Comparative Cardiovascular Safety of ADHD Medications

Concerns about the cardiovascular safety of medications used for th...

Read More

Label Update for Viloxazine ER: New Pharmacodynamic Data and Breastfeeding Info

The FDA has approved an update for the label for viloxazine ER to n...

Read More

Prevalence of ADHD in Adulthood

Despite the widespread prevalence of ADHD in adulthood, many patien...

Read More

Adult ADHD and Dementia

Every year NEI Fall Congress kicks off with multiple pre-conference...

Read More

October Is ADHD Awareness Month

October is ADHD Awareness Month. The goal of ADHD Awareness Month i...

Read More

Disrupted Access to Prescription Stimulant Medications

The Centers for Disease Control and Prevention (CDC) recently issue...

Read More

FDA Approves Liquid Non-Stimulant ADHD Medication

The US FDA has approved once-daily clonidine hydrochloride extended...

Read More

Stimulants and Sleep Difficulties in Pediatric ADHD

A recent comprehensive study delved into the long-term effects of m...

Read More

ADHD Pharmacotherapy and Mortality in Individuals With ADHD

A recent study explored whether initiation of ADHD pharmacotherapy ...

Read More

Why Medical Evaluation Should Be a Part of ADHD Assessment

Not all patients presenting with attentional/cognitive deficits and...

Read More

ADHD Medications and Long-Term Risk of Cardiovascular Diseases: New Data

This recently published case-control study explores the potential c...

Read More